USPTO serial 79443342
EFFIX
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- HARDY LUDLOW, TARAH KIM
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EFFIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eric Lamb
Eric Lamb FBT Gibbons LLP111 Monument Circle, Suite 4500Indianapolis, IN 46204United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations, other than for medical or veterinary purposes, for use in industry and science in connection with genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial purposes in scientific research and for use in pharmaceutical research; preparations of microorganisms, other than for medical and veterinary use; bacterial preparations, other than for medical and veterinary use; bacteriological preparations, other than for medical and veterinary use for use in industry and science in connection with genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial purposes in scientific research and for use in pharmaceutical research; biochemical reagents for scientific use; biochemical reagents, other than for medical use; collagen for industrial purposes; proteins for use in manufacture; protein for use in manufacture, namely, recombinant proteins expressed via microbial systems; proteins for industrial purposes; chemical additives for use in the manufacture of cosmetics; proteins for the food industry; proteins for use in the manufacture of cosmetics. | ACTIVE | — |
| 005 | Biological preparations for medical purposes for the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; preparations of microorganisms for medical use; pharmaceutical preparations for use in the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; medicines for human purposes for use in the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; cells for medical use; bacterial preparations for medical use; all the above-mentioned goods not intended to be used in the veterinary field. | ACTIVE | — |
| 040 | Custom manufacture of nanobodies, enzymes, cytokine, antibody fragments, virus-like particles, pDNA, antigens peptides, recombinant proteins, and vectors for others; processing and treatment of chemical reagents, namely, custom synthesis and manufacture of reagents for scientific or medical research use in the field of drug conjugation; custom manufacturing of cosmetics; custom manufacturing of pharmaceuticals; custom manufacture of biological preparations; custom manufacturing of biomedical preparations; custom manufacturing of biotechnology drugs; custom manufacturing of antibody drugs; custom manufacturing of biopharmaceuticals | ACTIVE | — |
| 042 | Consulting services in the field of technology development in the field of protein-related biological research; research and development of new products for others; scientific research and development; biochemical research and analysis; pharmaceutical products development services; pharmaceutical research services; research in the field of synthetic biology; development of pharmaceutical preparations and medicines; biomedical research services; scientific research and development services in the field of gene expression systems. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 10, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 10, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 10, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 10, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 8, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 8, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 8, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 8, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 8, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 8, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 8, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 9, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 20, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 20, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 17, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 16, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 16, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 15, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 12, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |